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Amanda Gammon, MS, CGC, and Karlen E. Luthy, DNP, FNPABSTRACT
One size does not ﬁt all for breast cancer screening. Early detection and prevention are most effective for
those most at risk. Several United States organizations recommend offering annual screening breast magnetic
resonance imaging in addition to mammography for women with > 20% lifetime risk for breast cancer using
models that take extensive family history into account. The purpose of this article is to help nurse
practitioners make critical decisions about breast cancer screening and referrals to genetic services for women
based on their lifetime risk for breast cancer. This article reviews several software-based risk assessment
models and provides instructions for using the Tyrer-Cuzick model.
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that would pose a conﬂict of interest.reast cancer is the second most diagnosed
cancer and the second leading cause of cancerBdeath in women.1,2 The American Cancer
Society (ACS) predicts 246,600 new cases of breast
cancer will be diagnosed in women during 2016 with
40,890 deaths.1 However, early detection, in
conjunction with appropriate screening, can decreaseThis CE learning activity is designed to augment the knowledge, skills, and attitudes of n
patients who are at elevated risk for breast cancer.
At the conclusion of this activity, the participant will be able to:
A. Compare/Contrast Breast CA screening guidelines for average risk and women with
B. Use the Tyrer Cuzick Model to calculate lifetime risk for Breast CA
C. Describe ways to identify/manage screening needs of elevated risk women
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www.npjournal.orgmortality associated with breast cancer.3-5 Nurse
practitioners assess breast cancer risk and recommend
screening for their patients in the primary care setting.
Primary care providers’ recommendations have a
strong inﬂuence on patient adherence to screening
guidelines.6,7 The purposes of this article are to
review breast cancer screening guidelines and tourse practitioners and assist in their understanding of how to best identify/manage
elevated risk
that would pose a conﬂict of interest.
reatment.
f Pharmacology. The activity is valid for CE credit until November 1, 2018.
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suggest an algorithm for nurse practitioners (NPs)
to use when assessing breast cancer risk and making
decisions about referral and breast cancer screening.
Finally, this article will provide instruction for NPs to
use the Tyrer-Cuzick model to calculate lifetime risk
for breast cancer.
SCREENING FOR WOMEN AT AVERAGE RISK
Breast cancer screening guidelines vary by organiza-
tion. The ACS updated its guidelines in October
2015 (Table 1). Key changes to the ACS guidelines
are the following: 1) annual clinical breast
examination is no longer recommended, 2) annual
mammograms are not to begin until age 45
(however, women should have the choice to begin
at age 40), and 3) at age 55 mammography should
switch to every other year (women may opt for
annual screening).3 The National Comprehensive
Cancer Network (NCCN) and the American
Congress of Obstetricians and Gynecologists still
recommend clinical breast examination at least every
3 years between ages 20 and 39 years and annually
from the age of 40 years on.8,9 These 2 organizations
recommend annual mammography for all women
beginning at age 40 years regardless of risk level.8,9 In
contrast, the United States Preventive Services Task
Force (USPSTF) guidelines, updated January 2016,
recommend biennial screening mammography for
women between ages 50 and 74 years (Table 1).10
SCREENING FOR WOMEN AT ELEVATED RISK
One size does not ﬁt all for breast cancer screening.
With the exception of the USPSTF, all of these or-
ganizations suggest more intensive screening for
women with elevated risk. Although the USPSTF
has not produced guidelines for women at elevated
risk, it acknowledges that its guidelines are not
intended for women at elevated risk.10 NPs should
identify women at elevated risk and offer more
intensive screening if warranted. The ACS, NCCN,
and American Congress of Obstetricians and
Gynecologists recommend that if a woman has
 20% lifetime risk for breast cancer, she should be
offered an annual screening breast magnetic
resonance imaging (MRI), in addition to annual
mammography.3,8,9 The addition of breast MRI
increases sensitivity in detecting breast cancerThe Journal for Nurse Practitioners - JNP582compared with mammography alone.11,12 NPs may
choose from a variety of models to calculate lifetime
risk for breast cancer.
CALCULATING LIFETIME RISK FOR BREAST CANCER
Several software-based models can estimate a woman’s
lifetime risk based on family history and other risk fac-
tors. Guideline-issuing organizations recommend using
only models that base risk calculations on extensive
family historywhen determining the need for screening
breast MRI.3,8 Some of these models include Claus,
BRCAPRO, Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm, and the
Tyrer-Cuzick.13-16 The Gail model is not appropriate
to use to determine the need for breast MRI because it
does not include enough family history.3,8
The Tyrer-Cuzick model is a well-studied, widely
available model for predicting breast cancer risk.16-18
This model includes the most comprehensive set of
variables and is the most sensitive of all the models for
detecting risk for breast cancer.17,19 The Tyrer-
Cuzick model is the only model to account for both
personal and extensive family history risk factors.16
Table 2 provides a list of personal risk factors for
breast cancer and indicates which ones are included
in the Tyrer-Cuzick model. Additionally, the Tyrer-
Cuzick model incorporates the presence of BRCA
gene mutations, personal risk factors, and extensive
family history.16,19,20 In this article, instructions are
provided for using the Tyrer-Cuzick model.
WHEN TO CALCULATE LIFETIME RISK FOR BREAST
CANCER
Using risk-calculating models is time intensive. To
use these models, NPs must collect extensive family
history, often necessitating more than 1 ofﬁce visit to
allow patients time to collect information from
extended family. It would not be feasible to calculate
lifetime risk for every patient. Therefore, NPs must
determine who needs more intensive risk assessment.
The annual examination can be a good time to do an
initial risk assessment as shown in Figure 1. NPs
should regularly update and review a woman’s family
history and assess other risk factors for breast cancer.
Women with concerning family history and/or
other risk factors may need further breast cancer risk
assessment. There are no clear guidelines suggesting aVolume 12, Issue 9, October 2016
Table 1. Breast Cancer Screening Recommendations by Organization and Risk Level
Organization
Screening Recommendations for Average Risk Women
Additional Recommendations
for Women With Elevated Risk
Clinical Breast
Examination
Breast
Self-examination
Breast
Self-awareness Mammography Screening Breast MRI
American Cancer Society
Latest update October 20153
No clear beneﬁt No clear beneﬁt Yes, be familiar with
normal feeling/appearance
Annual starting at 45
(women may choose
to start at 40) Every
other year starting at
55 (women may
choose to continue
annual)
Annually starting at age 30
if lifetime risk is calculated
at about 20%-25% or more
by models that take extensive
family history into account.
At lifetime risk of 15%-20%,
there is not enough evidence to
recommend for or against
screening breast MRI.
National Comprehensive
Cancer Network
Latest update
20158
Every 1-3 years
ages 25-40
Annually beginning 40
No, can be part
of awareness
Yes, be familiar with
normal feeling/appearance
Annually beginning
at age 40
Annually starting at age 30
if lifetime risk is calculated
at > 20% by models that
take extensive family history
into account
American Congress of
Obstetricians & Gynecologists
Last updated 2011,9
reafﬁrmed 2014
Every 3 years ages
20-39 Annually
beginning 40
No, can be part of
awareness
Yes, be familiar with
normal feeling/appearance
Annually beginning
at age 40
Annually starting at age 30
if lifetime risk is calculated
at  20% by models that take
extensive family history into
account
US Preventive Services Task
Force Latest update January 201610
Insufﬁcient evidence No, recommend
against teaching
No comment Every other year
ages 50-74
Does not provide
recommendations for
women with elevated risk
MRI ¼ magnetic resonance imaging.
w
w
w
.n
p
jo
urn
al.o
rg
T
h
e
Jo
u
rn
alfo
r
N
u
rse
P
ractitio
n
ers
-
JN
P
583
Table 2. Personal Risk Factors for Breast Cancer
Risk Factors
Advancing agea
Older age at ﬁrst live birth (> 30 y)a
Younger age at menarche (< 12 y)a
Older age at menopause (> 55 y)a
Hormone replacement therapya
Increased no. of breast biopsies
Increased breast density
Birth control
Radiation exposure
Decreased physical activity
Obesity
Alcohol use
Data from American Cancer Society (2015).3
a Indicates personal risk factor taken into account by Tyrer-Cuzick model.particular number or cluster of personal risk factors
necessitating further risk assessment. However,
certain family history characteristics are associated
with increased risk for breast cancer. If NPs suspect
women have such a family history, they should
provide further assessment (Figure 1).
If a woman needs further risk assessment, NPs can
either refer her to genetics professionals to receive
in-depth risk evaluation and lifetime risk calculations,
or NPs can perform their own calculations as part
of a risk assessment (Figure 1). If NPs prefer not
to perform their own risk calculations, they may
choose to look at guidelines listing concerning
family history characteristics21,22 (see Supplementary 1
“Indicators for Referral,” available online at http://
www.npjournal.org) or use a brief screening tool to
identify women appropriate for referral23 (see
Supplementary 2 “Brief Screening Tools,” available
online at http://www.npjournal.org). Alternatively,
with adequate education, NPs can use risk-calculating
software, such as the Tyrer-Cuzick model, to identify
women at  20% lifetime risk and order a breast
screening MRI if indicated. There are beneﬁts of NPs
performing their own risk calculations as opposed to
using brief screening tools. The brief screening tools
may miss at-risk women; alternatively, they may refer
low-risk women (D.O. Himes, personal
communication, August 2016). If NPs perform theirThe Journal for Nurse Practitioners - JNP584own calculations, it is helpful for women to receive
earlier risk assessment without going to an additional
appointment. Not everyone referred for genetic
counseling attends and receives a risk assessment.
Therefore, it may be advantageous to patients when
NPs calculate lifetime risk for breast cancer.
USING THE TYRER-CUZICK MODEL TO CALCULATE
LIFETIME RISK FOR BREAST CANCER
The Tyrer-Cuzick model is not difﬁcult to use. A
brief explanation of the steps and the order in which
they should be completed are as follows:
1. Step 1: download. Free software is available for
PC computers only at http://www.ems-trials.
org/riskevaluator/.
2. Step 2: begin. Click “evaluate” and then enter
the name and identiﬁcation number for the
consultand (Figure 2). A consultand is a person
for whom the provider is performing a risk
calculation. This person is identiﬁed on the
pedigree with an arrow.
3. Step 3: enter personal factors. Enter the con-
sultand’s age, age at menarche, and height and
weight measurements (Figure 3). There is an
option to convert the measurements of height
and weight from metric into imperial terms
(inches, pounds). Next, enter parity and then
history of breast disease in the consultand. If the
consultand has never been diagnosed with any
breast abnormalities, mark the no benign
disease box. If she has been diagnosed with
hyperplasia, unknown benign disease, atypical
hyperplasia, lobular carcinoma in situ, or
ovarian cancer, mark those boxes. NPs may
need to get biopsy records to conﬁrm
diagnoses. Next, enter the consultand’s
menopausal status. If she had surgical
menopause, enter the age she was at the time of
surgery in the “age at menopause” box. The
ﬁnal series of questions in the personal factors
section are related to hormone therapy (HRT).
NPs will need to enter data about the total
length of time HRT was used, how long it has
been since last used, and whether estrogen only
or combined (estrogen plus progesterone)
therapy was used. If the woman is currently
using HRT, a box will ask for intended lengthVolume 12, Issue 9, October 2016
Figure 1. Algorithm for assessing breast cancer risk: making decisions about referral to genetic services and
ordering breast MRI screening for women.
*Indicators for referral: joint guidelines published by the American College of Medical Genetics and the National Society of Genetic
Counselors as well guidelines published by the NCCN provide lists of family history characteristics appropriate for referral to genetic
specialist (see supplemental material “Indicators for Referral”). **Brief screening tool for referral: the USPSTF has recommended 5
tools to evaluate family history for the purpose of referral to genetic services (see supplemental material “Brief Screening Tools”).
wwof use. Finally, if the patient is of Ashkenazi
Jewish heritage (Eastern European Jewish),
mark the corresponding box because this
population is at increased risk for carrying
mutations in the BRCA1 and BRCA2 genes.
The ﬁnal task in the personal information
section is to check the competing mortality
box. Always check this box. With this boxw.npjournal.orgmarked, the calculations will include the
possibility that someone might die from causes
other than cancer before a breast cancer could
manifest. Leaving this box unchecked will
result in a higher lifetime risk calculation.
4. Step 4: family history; the most detailed sec-
tions of the Tyrer-Cuzick model involve
entering family history. As each step isThe Journal for Nurse Practitioners - JNP 585
Figure 2.Name and identiﬁcation number.
Figu
586completed, a pedigree drawing on the right
side will expand (Figure 4). An arrow on the
pedigree indicates which family member is the
consultand. The order in which this section is
completed matters. Clicking the buttons to there 3. Personal factors.
The Journal for Nurse Practitioners - JNPleft of the pedigree (see red box in Figure 4)
should be done last. The pop-up windows
generated by clicking these buttons will vary
depending on what has been entered in the
previous portions of the family history.Volume 12, Issue 9, October 2016
Figure 4. Family history; click buttons in red box last.The overall objective with the family history
section is to include family history that would in-
ﬂuence the woman’s risk for breast cancer. All rela-
tives and all conditions will not be included. For
sisters, aunts, and daughters, the number of women in
each category will need to be entered before their
cancer history. The program will accept cancer his-
tory for up to 5 relatives in each of these categories.
Because not all relatives can be included, NPs should
preferentially choose to include relatives with cancer
to account for the family risk.
Once the number of ﬁrst- or second-degree
female relatives is entered, NPs will need to enter
current age or age of death for mother, sisters,
grandmothers, aunts, and daughters. If any of these
women have had ovarian, bilateral breast cancer, or
breast cancer, mark those boxes, and enter the age of
cancer onset rather than current age or age of death.
If a woman has had either bilateral breast cancer or 2
primary breast cancers in the same breast, the
“bilateral” box should be checked to account for the
risk where that option is available.
After the initial family history has been
completed, systematically click the buttons outlined
in red (Figure 4). The ﬁrst button to click is male
relatives. If consultand’s brother or father has hadwww.npjournal.orgbreast cancer, check the box, and enter age at breast
cancer diagnosis. Next is a button for half sisters. The
NP can record up to 2 paternal and 2 maternal half
sisters. Check the breast cancer box if they have had
breast cancer, and enter age of onset; if they have not
had breast cancer, enter current age. Clicking the
“affected cousins” button will open a pop-up win-
dow titled “cousin data” (Figure 5). Some
information will already be entered based on previous
information given.
The model only allows for children of up to 2
aunts and 1 uncle to be entered as affected on each
side of the family. Preferentially enter aunts with
children (consultand’s cousins) who have cancer.
Version 7 of the IBIS Risk Evaluator software will
also allow for ovarian cancer to be accounted for in
this section.
Next, click the “affected nieces” button. A pop-
up window titled “niece data” will open (Figure 6).
The model will only allow for affected daughters of 3
sisters (consultand’s nieces) and 1 brother to be
entered. If none are affected, no additional
information is necessary to be entered in this section.
The last of the buttons in this section is the
“genetic testing” button. Clicking this button brings
up the pop-up box titled “genetic testing results”The Journal for Nurse Practitioners - JNP 587
Figure 5. Cousin data.seen in Figure 7. Here, NPs will enter genetic test
results, if available, for the consultand, paternal and
maternal grandmothers, paternal and maternal aunts,
father, sisters, mother, and daughters. The Tyrer-
Cuzick model only accepts test results to be entered
for 2 paternal and 2 maternal aunts, 3 sisters, and 2
daughters. Preferentially enter information for
women affected with breast cancer. If no test has
been performed, check no test. If testing has been
completed and it was negative, check negative. If the
consultand or family member is positive for BRCA1
or BRCA2 gene mutations, mark those respectively.
5. Step 5: calculating risk; after entering in all
necessary information, click the calculate risk
button in the upper right corner of the main
screen. The consultand’s level of risk will be
displayed in a graph and percent format similar
to Figure 8. Multiple calculations are provided.
NPs will see a lifetime risk calculation, as wellThe Journal for Nurse Practitioners - JNP588as a 10-year risk. If NPs would like to see a risk
level for an amount of years other than 10, a
different number can be entered by clicking
the “risk options” button in the upper right
corner. The software provides a comparison of
the consultand’s risk of having breast cancer
with the general population risk. The number
to focus on for ordering screening breast MRI
is the lifetime risk calculation. This ﬁnal screen
will also provide the consultand’s risk of having
the BRCA1 and BRCA2 gene mutations. If
the consultand’s personal risk level for a mu-
tation is  10%, consider referral for genetic
testing.24
LIMITATIONS OF BREAST CANCER RISK ASSESSMENT
Breast cancer risk assessment can be a moving target.
Updates to risk assessment models and guidelines are
actively being explored. Adding risk factors such asVolume 12, Issue 9, October 2016
Figure 6.Niece data.breast density25 and single nucleotide polymorphism
genetic testing panel data to risk models are being
considered to further reﬁne risk calculations.
Additionally, although guidelines are currently based
on lifetime risk, emerging literature suggests a move
to a 10-year risk window may provide more con-
sistency between models and would allow for more
large-scale validation studies.26
There are some limitations in using the Tyrer-
Cuzick model in particular. This model accounts
only for hereditary breast and ovarian cancer
(HBOC), the most common of the hereditary breast
cancer syndromes. HBOC is caused by a mutation in
the BRCA1 and BRCA2 genes.27 Many other
hereditary breast cancer syndromes exist that increase
a woman’s risk of developing breast cancer. These
syndromes and their affected genes include TP53
mutations in Li-Fraumeni syndrome, PTEN muta-
tions in Cowden syndrome, STK11 mutations in
Peutz-Jeghers syndrome, and CDH1 in hereditary
diffuse gastric cancer.28 More can be read about these
syndromes at the Genetics Home Reference website
published by the National Institutes of Health. If a
woman presents with any of these syndromes, awww.npjournal.orggenetic counselor should be consulted, regardless of
Tyrer-Cuzick calculation.
The Tyrer-Cuzick model cannot account for
other concerning family history. According to the
NCCN, women should be referred to a genetic
counselor if they have a family history of 3 or more of
the following: “breast, pancreatic cancer, prostate
cancer (Gleason score  7), melanoma, sarcoma,
adrenocortical carcinoma, brain tumors, leukemia,
diffuse gastric cancer, colon cancer, endometrial
cancer, thyroid cancer, kidney cancer, dermatologic
manifestations and/or macrocephaly, hamartomatous
polyps of the GI [gastrointestinal] tract.”29
MANAGEMENT OF WOMEN WITH ELEVATED RISK
If a woman’s lifetime risk is  20%, annual screening
breast MRI should be considered.8 Breast MRI
should be offered in addition to annual breast
mammography because mammography may detect
some breast cancers missed by MRI.3 Pros and cons
of annual MRI screening need to be a part of the
discussion. Although MRI increases sensitivity for
identifying breast cancer in high-risk women, there is
also risk of false positives, which could lead toThe Journal for Nurse Practitioners - JNP 589
Figure 7.Genetic testing results.unnecessary biopsies. Cost is also a factor. Although
mammograms are covered as preventative services by
most plans (covered at 100% regardless of unmet
deductible), breast MRI is not. Documentation of
lifetime risk calculations will increase the likelihood
of having MRI covered.
Because management of these women can be
complex, interdisciplinary management is recom-
mended. The NCCN recommends that primary care
providers refer patients with elevated lifetime risk
calculations > 20% for genetic counseling (Figure 1).
Genetic counselors and medical geneticists are trained
to evaluate pedigrees and assess for which gene
mutations to test. Although mutations in BRCA1
and BRCA2 account for most hereditary breast
cancer syndromes, many others exist. If patients are
found to carry an autosomal dominant gene
mutation, special follow-up is required. However,
even if no mutation is identiﬁed, patients may be
considered high risk based on family history alone.
NCCN guidelines suggest that women with a life-
time risk > 20%, as deﬁned by assessment models that
take extensive family history into account (such as theThe Journal for Nurse Practitioners - JNP590Tyrer-Cuzick model), should receive the following
beginning 10 years before the onset of cancer in the
family: annual screening mammogram, annual breast
MRI (alternate every 6 months), clinical breast ex-
amination every 6 to 12 months, and participation in
breast awareness.8
It is important to note that calculating lifetime risk
is not the only component of a risk assessment and
ordering screening breast MRI is not the only pre-
vention/surveillance intervention for women at
elevated risk. In addition to screening breast MRI,
women with elevated risk also beneﬁt from risk
reduction strategies including lifestyle modiﬁcations
and chemoprevention.30 It is beyond the scope of this
article to describe all appropriate interventions for
women at elevated risk.
Women should have their breast cancer risk
reassessed periodically. A woman’s remaining lifetime
risk for breast cancer changes over time. Although
she may have a risk over 20% at age 35, risk may not
be as high at age 60 because she has lived through
more of her lifetime risk. Additionally, if other can-
cers are diagnosed in the family or if geneticVolume 12, Issue 9, October 2016
Figure 8. Risks.mutations are identiﬁed, risk may increase. There-
fore, risk assessment is not a 1-time event.
BILLING
The USPSTF has determined the screening and
referral of women to genetic services for counseling
and testing if appropriate is a level B recommenda-
tion, meaning there is sufﬁcient evidence to recom-
mend the service. According to the Affordable
Care Act, preventive measures rated level A or B
by the USPSTF must be covered without copay-
ment by the patient.31 Therefore, if primary care
providers determine patients need referral to
genetic counselors, the services should be covered
by insurance.
Consulting with patients about breast cancer risk
is reimbursable if the NP uses the appropriate Inter-
national Statistical Classiﬁcation of Diseases, 10th Revision
(ICD-10) and Current Procedural Terminology codes.
Potential ICD-10 codes eligible for reimbursement
include Z31.5 (encounter for genetic counseling),www.npjournal.orgZ15.01 (encounter for genetic counseling [Z15.01 is
not a principal or ﬁrst-listed code; it may be used in
conjunction with Z31.5. If used together, Z31.5
must be listed ﬁrst]), Z80.3 (family history of malig-
nant neoplasm of breast), and Z80.41 (family history
of malignant neoplasm of ovary). However, the ICD-
10 code must be billed in conjunction with a 96040
(medical genetics and genetic counseling services,
each 30 minutes face-to-face with patient/family)
Current Procedural Terminology code.32
CONCLUSION
Women at elevated risk for breast cancer rarely
receive screening breast MRI as recommended by
several US guidelines. It may be that many clinicians
are not familiar with or do not use risk-calculating
software. This article reviewed current guidelines
regarding breast MRI and instructions for use of the
most accessible and comprehensive risk calculation
model. Furthermore, this article suggested an algo-
rithm for NPs to use when assessing breast cancer riskThe Journal for Nurse Practitioners - JNP 591
and making decisions about referral and breast cancer
screening. However, risk assessment and any in-
dividual’s breast cancer risk are moving targets. This is
a rapidly changing ﬁeld, and tools and guidelines will
continue to change. Therefore, practitioners need to
stay abreast of new developments.
SUPPLEMENTARY DATA
Supplementary tables associated with this article can
be found in the online version at http://dx.doi.org/
10.1016/j.nurpra.2016.07.027.
References
1. American Cancer Society. Cancer facts and ﬁgures. http://www.cancer.org/
acs/groups/content/@research/documents/document/acspc-047079.pdf.
2016. Accessed May 4, 2016.
2. National Cancer Institute. Surveillance, epidemiology, and end results
program. http://seer.cancer.gov/statfacts/html/breast.html. 2015. Accessed
May 4, 2016.
3. American Cancer Society. American cancer society recommendations for
early breast cancer detection in women without breast symptoms. http://
www.cancer.org/cancer/breastcancer/moreinformation/
breastcancerearlydetection/breast-cancer-early-detection-acs-recs. 2015.
Accessed May 4, 2016.
4. Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival
after lumpectomy and mastectomy for early stage invasive breast
cancer: the effect of age and hormone receptor status. Cancer.
2013;119(7):1402-1411.
5. Tilanus-Linthorst MMA, Bartels CCM, Obdeijn AIM, Oudkerk M. Earlier
detection of breast cancer by surveillance of women at familial risk. Eur J
Cancer. 2000;36(4):514-519.
6. Fulton JP, Buechner JS, Scott HD, et al. A study guided by the Health Belief
Model of the predictors of breast cancer screening of women ages 40 and
older. Public Health Rep. 1991;106(4):410-420.
7. Klabunde CN, Schenck AP, Davis WW. Barriers to colorectal cancer screening
among Medicare consumers. Am J Prev Med. 2006;30(4):313-319.
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in
oncology: breast cancer screening and diagnosis. http://www.nccn.org/
professionals/physician_gls/pdf/breast-screening.pdf. 2015.AccessedMay4,2016.
9. ACOG. Practice bulletin number 122 breast cancer screening. The American
College of Obstetricians and Gynecologists; August 2011;118(2 Part 1).
10. U.S. Preventitive Services Task Force. Breast cancer: screening. http://www
.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/
breast-cancer-screening1. 2016. Accessed April 15, 2016.
11. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with
addition of annual screening ultrasound or a single screening MRI to
mammography in women with elevated breast cancer risk. JAMA.
2012;307(13):1394-1404.
12. Chiarelli AM, Prummel MV, Muradali D, et al. Effectiveness of screening with
annual magnetic resonance imaging and mammography: results of the initial
screen from the ontario high risk breast screening program. J Clin Oncol.
2014;32(21):2224-2230.
13. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic
susceptibility to breast and ovarian cancers: updates and extensions. Br J
Cancer. 2008;98(8):1457-1466.
14. Berry DA, Iversen ES Jr., Gudbjartsson DF, et al. BRCAPRO validation,
sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast
cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701-2712.The Journal for Nurse Practitioners - JNP59215. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-
onset breast cancer. Implications for risk prediction. Cancer.
1994;73(3):643-651.
16. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating
familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.
17. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of
breast cancer: a review of risk assessment models. J Natl Cancer Inst.
2010;102(10):680-691.
18. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and
similarities in breast cancer risk assessment models in clinical practice: which
model to choose? Breast Cancer Res Treat. 2009;115(2):381-390.
19. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk
assessment packages in the family history evaluation and screening
programme. J Med Genet. 2003;40(11):807-814.
20. Ozanne EM, Drohan B, Bosinoff P, et al. Which risk model to use? Clinical
implications of the ACS MRI screening guidelines. Cancer Epidemiol
Biomarkers Prev. 2013;22(1):146-149.
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines
in oncology: genetic/familial high-risk assessment: breast and ovarian. http://
www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. 2015.
Accessed June 18, 2016.
22. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice
guideline from the American College of Medical Genetics and Genomics and
the National Society of Genetic Counselors: referral indications for cancer
predisposition assessment. Genet Med. 2015;17(1):70-87.
23. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk
assessment, genetic counseling, and genetic testing for BRCA-related cancer
in women: a systematic review to update the U.S. Preventive Services Task
Force recommendation. Ann Intern Med. 2014;160(4):255-266.
24. National Institute for Health and Care Excellence (NICE). Familial breast
cancer: classiﬁcation, care and managing breast cancer and related risks in
people with a family history of breast cancer. https://www.nice.org.uk/
guidance/cg164/chapter/1-recommendations#genetic-testing. 2015. Accessed
September 6, 2016.
25. Bretnnall AR, Harkness EF, Astley SM, et al. Mammographic density adds
accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a
prospective UK screening cohort. Breast Cancer Res. 2015;17(1):147.
26. Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.
Practical problems with clinical guidelines for breast cancer
prevention based on remaining lifetime risk. J Natl Cancer Inst.
2015;107(7):djv124.
27. LeGrazie B. Counseling high-risk women about breast cancer. Oncology
(Williston Park). 2011;25(2 Suppl Nurse Ed):30-35.
28. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility
genes. Biomed Res Int. 2013;2013:747318.
29. Raikhlin A, Curpen B, Warner E, Betel C, Wright B, Jong R. Breast MRI as an
adjunct to mammography for breast cancer screening in high-risk patients:
retrospective review. AJR Am J Roentgenol. 2015;204:889-897.
30. National Comprehensive Cancer Network. NCCN clinical practice guidelines
in oncology: breast cancer risk reduction. Version1.2016. https://www.nccn
.org/professionals/physician_gls/pdf/breast_risk.pdf. 2016. Accessed June 15,
2016.
31. Centers for Medicare & Medicaid Services. The center for consumer
information & insurance oversight: affordable care act implementation FAQs-
set 12. http://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_
implementation_faqs12.html. 2013. Accessed May 4, 2016.
32. Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/
coding/icd10/downloads/2016-icd-10-cm-guidelines.pdf. 2016. Accessed June
23, 2016.1555-4155/16/$ see front matter
© 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.nurpra.2016.07.027Volume 12, Issue 9, October 2016
